These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 25628093)

  • 21. Expression of Placenta Growth Factor Is Associated with Unfavorable Prognosis of Advanced-Stage Serous Ovarian Cancer.
    Meng Q; Duan P; Li L; Miao Y
    Tohoku J Exp Med; 2018 Apr; 244(4):291-296. PubMed ID: 29643276
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors.
    Kaipio K; Chen P; Roering P; Huhtinen K; Mikkonen P; Östling P; Lehtinen L; Mansuri N; Korpela T; Potdar S; Hynninen J; Auranen A; Grénman S; Wennerberg K; Hautaniemi S; Carpén O
    J Pathol; 2020 Feb; 250(2):159-169. PubMed ID: 31595974
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of PH Domain Leucine-rich Repeat Protein Phosphatase, Forkhead Homeobox Type O 3a and RAD51, and their Relationships with Clinicopathologic Features and Prognosis in Ovarian Serous Adenocarcinoma.
    Zhang J; Wang JC; Li YH; Wang RX; Fan XM
    Chin Med J (Engl); 2017 Feb; 130(3):280-287. PubMed ID: 28139510
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer.
    Steffensen KD; Waldstrøm M; Jakobsen A
    Int J Gynecol Cancer; 2009 Jul; 19(5):820-5. PubMed ID: 19574766
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.
    Gershenson DM; Sun CC; Bodurka D; Coleman RL; Lu KH; Sood AK; Deavers M; Malpica AL; Kavanagh JJ
    Gynecol Oncol; 2009 Jul; 114(1):48-52. PubMed ID: 19361839
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Down-regulation of HECTD3 by HER2 inhibition makes serous ovarian cancer cells sensitive to platinum treatment.
    Shu T; Li Y; Wu X; Li B; Liu Z
    Cancer Lett; 2017 Dec; 411():65-73. PubMed ID: 28989055
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Distinct subtypes of serous ovarian carcinoma identified by p53 determination.
    Lassus H; Leminen A; Lundin J; Lehtovirta P; Butzow R
    Gynecol Oncol; 2003 Dec; 91(3):504-12. PubMed ID: 14675668
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Carcinosarcoma of the ovary compared to ovarian high-grade serous carcinoma: impact of optimal cytoreduction and standard adjuvant treatment.
    Yalcin I; Meydanli MM; Turan AT; Taskin S; Sari ME; Gungor T; Akbayir O; Ayhan A
    Int J Clin Oncol; 2018 Apr; 23(2):329-337. PubMed ID: 29143144
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance.
    Ricciardelli C; Lokman NA; Pyragius CE; Ween MP; Macpherson AM; Ruszkiewicz A; Hoffmann P; Oehler MK
    Oncotarget; 2017 Mar; 8(11):17819-17832. PubMed ID: 28147318
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression profiles of PRKG1, SDF2L1 and PPP1R12A are predictive and prognostic factors for therapy response and survival in high-grade serous ovarian cancer.
    Benvenuto G; Todeschini P; Paracchini L; Calura E; Fruscio R; Romani C; Beltrame L; Martini P; Ravaggi A; Ceppi L; Sales G; Donati F; Perego P; Zanotti L; Ballabio S; Grassi T; Delle Marchette M; Tognon G; Sartori E; Adorni M; Odicino F; D'Incalci M; Bignotti E; Romualdi C; Marchini S
    Int J Cancer; 2020 Jul; 147(2):565-574. PubMed ID: 32096871
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Primary and acquired platinum-resistance among women with high grade serous ovarian cancer.
    Slaughter K; Holman LL; Thomas EL; Gunderson CC; Lauer JK; Ding K; McMeekin DS; Moore KM
    Gynecol Oncol; 2016 Aug; 142(2):225-30. PubMed ID: 27208536
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic impact of the cancer stem cell-related marker NANOG in ovarian serous carcinoma.
    Lee M; Nam EJ; Kim SW; Kim S; Kim JH; Kim YT
    Int J Gynecol Cancer; 2012 Nov; 22(9):1489-96. PubMed ID: 23095773
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glutathione concentration may be a useful predictor of response to second-line chemotherapy in patients with ovarian cancer.
    Kigawa J; Minagawa Y; Kanamori Y; Itamochi H; Cheng X; Okada M; Oishi T; Terakawa N
    Cancer; 1998 Feb; 82(4):697-702. PubMed ID: 9477102
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-beta pathway signaling indicates response to primary chemotherapy.
    Carey MS; Agarwal R; Gilks B; Swenerton K; Kalloger S; Santos J; Ju Z; Lu Y; Zhang F; Coombes KR; Miller D; Huntsman D; Mills GB; Hennessy BT
    Clin Cancer Res; 2010 May; 16(10):2852-60. PubMed ID: 20460476
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination of serum hCG beta and p53 tissue expression defines distinct subgroups of serous ovarian carcinoma.
    Vartiainen J; Lassus H; Lehtovirta P; Finne P; Alfthan H; Butzow R; Stenman UH
    Int J Cancer; 2008 May; 122(9):2125-9. PubMed ID: 18098286
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant Chemotherapy Followed by Maintenance Therapy With or Without Bevacizumab in Unresectable High-Grade Serous Ovarian Cancer: A Case-Control Study.
    Petrillo M; Paris I; Vizzielli G; Amadio G; Cosentino F; Salutari V; Scambia G; Fagotti A
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S952-8. PubMed ID: 26036187
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EphA5 protein, a potential marker for distinguishing histological grade and prognosis in ovarian serous carcinoma.
    Chen X; Wang X; Wei X; Wang J
    J Ovarian Res; 2016 Nov; 9(1):83. PubMed ID: 27887627
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Correlations of EGFR and LRP to chemotherapy resistance and prognosis of ovarian cancer].
    Zhang J; Chen AP; Wang B; Zhao SP; Liu LZ; Dai SZ
    Ai Zheng; 2008 Dec; 27(12):1331-6. PubMed ID: 19080004
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ERBB4 Expression in Ovarian Serous Carcinoma Resistant to Platinum-Based Therapy.
    Saglam O; Xiong Y; Marchion DC; Strosberg C; Wenham RM; Johnson JJ; Saeed-Vafa D; Cubitt C; Hakam A; Magliocco AM
    Cancer Control; 2017 Jan; 24(1):89-95. PubMed ID: 28178720
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression and clinical role of chemoresponse-associated genes in ovarian serous carcinoma.
    Nymoen DA; Hetland Falkenthal TE; Holth A; Ow GS; Ivshina AV; Tropé CG; Kuznetsov VA; Staff AC; Davidson B
    Gynecol Oncol; 2015 Oct; 139(1):30-9. PubMed ID: 26232338
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.